Pre-earnings brief
Reports
Tue, Nov 3, 2026
Est. EPS
—
Est. revenue
—
Implied move
±6.7%
EPS beat rate
100%
Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines. Operating in the Health Care sector, Pfizer plays a crucial role in addressing global health challenges, particularly in infectious diseases and chronic conditions.
Last quarter
In Q2 2026, Pfizer reported an EPS of $0.77, surpassing expectations by nearly 14%. The stock reacted positively, gaining 1.52% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+30.82%
Avg 1-day reaction
+0.38%
Investors are cautiously optimistic about Pfizer's upcoming earnings, given its strong track record of beating EPS estimates. However, there is uncertainty surrounding revenue figures and future guidance.
Bull case
If Pfizer continues its trend of exceeding EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a stock price increase.
Bear case
Conversely, if revenue growth falls short or management provides weak guidance, it could lead to a negative reaction from the market.
The print will turn on these.
Q1
What is the projected revenue growth rate for new products launched this quarter?
This will indicate Pfizer's ability to innovate and capture market share, which is crucial for future profitability.
Q2
How does management view the competitive landscape for its key therapies?
Understanding competitive pressures will help investors gauge Pfizer's market position and potential challenges ahead.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±8.7%
Why consensus could be wrong
The Street may be underestimating the impact of Pfizer's recent product launches, which could drive stronger-than-expected revenue growth.
Supporting evidence
Pfizer has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.
Recent insider selling could suggest that some insiders are positioning for a short-term dip, contrary to bullish sentiment.
Key risk
If revenue growth exceeds 10%, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The market is debating Pfizer's ability to sustain growth amid increasing competition and market pressures.
Bull confirmed if
Revenue growth of 10% or more compared to the previous quarter would confirm the bull case.
Bear confirmed if
Any revenue decline or lack of guidance for future growth would confirm the bear case.
What the market is pricing for the move.
Implied Move
±6.74%
Historical Avg
±2.2%
The options market is pricing in a significant move around the earnings report, suggesting heightened investor uncertainty.
Options are pricing ±6.7% while PFE has averaged ±2.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
15.7%
Smart-money positioning from the most recent 13F filings.
Institutional
69.16%
of float
Insider
0.10%
of float
Holders
3,618
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
529,670,433 sh · $14.8B
9.29%
6.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Pfizer beats expectations and raises guidance, history suggests the stock could rise by around 0.38% on the next trading day.
In line / cautious
If results are in line but management is cautious, the stock may see a muted response as investors reassess future growth.
Miss
If Pfizer misses expectations, history suggests a potential decline of around 0.38% on the next trading day.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
Senate only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
372,149,852 sh · $10.4B
6.53%
0.7%
State Street Corporation
307,090,897 sh · $8.6B
5.39%
1.8%
Geode Capital Management, LLC
135,275,782 sh · $3.8B
2.37%
1.3%
Vanguard Portfolio Management LLC
119,235,030 sh · $3.3B
2.09%
2.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jun 8, 2026 · disclosed Jul 16, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.